Pharmacyclics (PCYC) 10-Q 4 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 24, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	PHARMACYCLICS INC
Entity Central Index Key	949699
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	76,791,635,000	77,079,177
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$874,684	$845,035
Marketable securities	11,958	11,952
Accounts receivable, net	76,983	64,297
Receivable from collaboration partners	24,025	26,970
Inventory	49,025	34,446
Advances to manufacturers	1,149	12,288
Prepaid expenses and other current assets	39,953	20,571
Total current assets	1,077,777	1,015,559
Property and equipment, net	32,141	32,476
Intangible assets, net	8,550	8,730
Other assets	3,429	3,342
Total assets	1,121,897	1,060,107
Current liabilities:
Accounts payable	2,889	7,315
Accrued liabilities	95,439	88,279
Payable to collaboration partner	77,460	79,799
Income tax payable	53	70
Deferred revenue - current portion	18,797	18,773
Total current liabilities	194,638	194,236
Deferred revenue - non-current portion	32,757	34,885
Other long-term liabilities	1,836	1,821
Total liabilities	229,231	230,942
Commitments and contingencies (see Notes 3 and 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2015 and December 31, 2014, respectively; shares issued and outstanding 76,791,635 and 75,933,661 at March 31, 2015 and December 31, 2014, respectively	8	8
Additional paid-in capital	1,018,985	959,637
Accumulated other comprehensive loss	-2	-8
Accumulated deficit	-126,325	-130,472
Total stockholders’ equity	892,666	829,165
Total liabilities and stockholders’ equity	$1,121,897	$1,060,107

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	76,791,635	75,933,661
Common stock, shares outstanding (in shares)	76,791,635	75,933,661

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Product revenue, net	$189,158	$56,179
Alliance revenue, net	12,525	0
Collaboration services and other revenue	4,089	3,198
License and milestone revenue	0	60,000
Total revenue	205,772	119,377
Costs and expenses:
Cost of goods sold	16,702	6,110
Research and Development Expense	49,377	35,292
Selling, general and administrative	49,505	34,715
Costs of collaboration (see Note 3)	86,228	25,035
Amortization of intangible assets (see Note 7)	179	0
Total costs and expenses	201,991	101,152
Income from operations	3,781	18,225
Interest income	167	80
Other income (expense), net	285	-42
Income before income taxes	4,233	18,263
Income tax provision (benefit)	86	-12
Net income	$4,147	$18,275
Net income per share:
Basic (in dollars per share)	$0.05	$0.24
Diluted (in dollars per share)	$0.05	$0.23
Weighted average shares used to compute net income per share:
Basic (in shares)	76,205	74,754
Diluted (in shares)	79,231	78,064

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Comprehensive income, net of taxes
Net income	$4,147	$18,275
Change in unrealized gain (loss) on marketable securities	6	-1
Comprehensive income, net of tax	$4,153	$18,274

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$4,147	$18,275
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	1,410	911
Stock-based compensation expense	23,496	12,986
Excess tax benefit from stock-based compensation arrangements	-18,021	0
Income tax benefit from stock-based compensation arrangements	-18,021	0
Provision for bad debts	-6	0
Changes in assets and liabilities:
Accounts receivable	-12,680	-15,969
Receivable from collaboration partners	2,945	50,910
Inventory	-14,515	-15,799
Advances to manufacturers	11,139	5,478
Prepaid expenses and other assets	-19,367	-2,564
Accounts payable	-4,426	-2,806
Accrued liabilities	7,383	-7,046
Payable to collaboration partner	-2,339	14,502
Income taxes payable	-17	-1,418
Deferred revenue	-2,104	-2,096
Other long-term liabilities	15	96
Net cash provided by (used in) operating activities	-4,919	55,460
Cash flows from investing activities:
Purchase of property and equipment	-1,119	-6,211
Purchase of marketable securities	-2,640	-2,640
Proceeds from maturities of marketable securities	2,640	2,880
Net cash used in investing activities	-1,119	-5,971
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock plans	18,226	5,180
Tax payments related to shares withheld for vested restricted stock units	-560	0
Excess tax benefit from stock-based compensation arrangements	18,021	0
Net cash provided by financing activities	35,687	5,180
Increase in cash and cash equivalents	29,649	54,669
Cash and cash equivalents at beginning of period	845,035	623,956
Cash and cash equivalents at end of period	874,684	678,625
Supplemental disclosure of non-cash investing and financing activities:
Receivable for stock option exercises	137	5
Property and equipment purchases included in Accounts payable and Accrued liabilities	$793	$3,068

The_Company_and_Significant_Ac

The Company and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
The Company and Significant Accounting Policies	The Company and Significant Accounting Policies
	Company Overview
	Pharmacyclics, Inc. (Pharmacyclics or the Company) is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics markets IMBRUVICA® (ibrutinib) and has other product candidates in clinical development and several preclinical molecules in lead optimization.
	IMBRUVICA is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson.
	IMBRUVICA currently is approved for use in approximately 47 countries including the U.S., Canada, and the 28 member countries which comprise the European Union (EU).
	IMBRUVICA first came to market on November 13, 2013, when it was approved by the U.S. Food and Drug Administration (FDA) under accelerated approval as a single agent for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Improvements in survival or disease symptoms have not been established. On February 12, 2014, the FDA approved IMBRUVICA under accelerated approval as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. On July 28, 2014, IMBRUVICA received regular (full) FDA approval for the treatment of patients with CLL who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naive and previously treated del 17p patients. On October 17, 2014, the European Commission (EC) granted marketing approval for IMBRUVICA in the EU for the treatment of adult patients with relapsed or refractory MCL, or adult patients with CLL who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemoimmunotherapy. On January 29, 2015, single-agent ibrutinib received regular (full) FDA approval for patients with Waldenström's macroglobulinemia (WM), and it is approved in all lines of therapy.
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Pharmacyclics, Inc. and its wholly-owned subsidiaries, Pharmacyclics (Europe) Limited, Pharmacyclics Switzerland GmbH, Pharmacyclics Cayman Ltd. and Pharmacyclics (Shanghai) Management Consulting Service Limited. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations.
	The interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with Article 10 of Regulation S-X which governs quarterly reporting and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of the Company's financial position, results of operations and cash flows in accordance with United States generally accepted accounting principles (GAAP). The December 31, 2014 condensed consolidated balance sheet data contained within this Form 10-Q was derived from audited consolidated financial statements included in the Company's Form 10-K for the year ended December 31, 2014, but does not include all disclosures required by accounting principles generally accepted in the United States.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all normal and recurring adjustments necessary for a fair statement of the results of operations, financial position and cash flows. These condensed consolidated financial statements should be read in conjunction with the financial statements included in the Company's Form 10-K for the year ended December 31, 2014. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in the Company's condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
	Significant Accounting Policies
	The Company's significant accounting policies were described in Note 2 to its consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2014. There have been no significant changes to the Company's accounting policies since December 31, 2014.
	Concentration of credit risk
	Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, marketable securities, accounts receivable and the receivable from collaboration partners. The Company places its cash and cash equivalents with high-credit quality financial institutions and invests in debt instruments of financial institutions, corporations and government entities with strong credit ratings. The Company's management believes it has established guidelines relative to credit quality, diversification and maturities that maintain safety and liquidity.
	The Company sells IMBRUVICA to some customers who have in-house dispensing capabilities, specialty pharmacies (SP) that sell to individual patients, specialty distributors (SD) that sell to hospital pharmacies and other organizations that we have contracted with. The Company continuously monitors the creditworthiness of its customers and has internal policies regarding customer credit limits. The Company's policy is to estimate the allowance for doubtful accounts based on the credit worthiness of its customers, historical payment patterns, the aging of accounts receivable balances and general economic conditions. As of March 31, 2015 and December 31, 2014, the Company had no significant allowance for doubtful accounts. As of March 31, 2015, four individual customers accounted for 22%, 20%, 19% and 18% of gross accounts receivable. As of December 31, 2014, four individual customers accounted for 25%, 22%, 19% and 15% of gross accounts receivable.

Product_Revenue_Net

Product Revenue, Net	3 Months Ended
	Mar. 31, 2015
Revenues [Abstract]
Product Revenue, Net	Product Revenue, Net
	Product revenue, net consists of revenue recorded from the sale of IMBRUVICA. The Company sells IMBRUVICA directly to some customers who have in-house dispensing capabilities, specialty pharmacies (SP) that sell to individual patients, specialty distributors (SD) that sell to hospital pharmacies and other organizations that the Company has contracted with.
	The following table summarizes the provisions, and credits/payments, for product revenue, net of adjustments (in thousands):
		Total
	Balance as of December 31, 2014	$	26,735
	Provision related to current period product revenue	28,779
	Credits/payments	(20,972		)
	Balance as of March 31, 2015	$	34,542
		Total
	Balance as of December 31, 2013	$	1,206
	Provision related to current period product revenue	8,639
	Credits/payments	(2,095		)
	Balance as of March 31, 2014	$	7,750
	The following table sets forth customers who represented 10% or more of the Company's product revenue, net for the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
	Customer	2015			2014
	A	29	%		29	%
	B	21	%		19	%
	C	16	%		12	%
	D	13	%		8	%
	E	10	%		13	%

Collaboration_and_Other_Agreem

Collaboration and Other Agreements	3 Months Ended
	Mar. 31, 2015
Collaboration and Other Agreements [Abstract]
Collaboration and Other Agreements	Collaboration and Other Agreements
	Collaboration and License Agreement with Janssen
	Background
	In December 2011, the Company entered into a worldwide collaboration and license agreement (the Agreement) with Janssen for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton’s Tyrosine Kinase (BTK), and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the U.S. and outside the U.S.
	The collaboration provides Janssen with an exclusive license to commercialize Licensed Products (as defined in the Agreement) outside of the U.S. (the "License Territory," "ex-U.S.") and co-exclusively with Pharmacyclics in the U.S. Both parties are responsible for the development, manufacturing and marketing of any products resulting from the Agreement. The Company continues to work with Janssen on protocols and the design, schedules and timing of trials.
	The collaboration has no set duration or specific expiration date and provided for payments by Janssen to the Company of a $150.0 million non-refundable upfront payment upon execution, as well as potential future milestone payments of up to $825.0 million, based upon continued development progress ($250.0 million), regulatory progress ($225.0 million) and approval of the product in both the U.S. and the License Territory ($350.0 million). As of March 31, 2015, $605.0 million in milestone payments had been earned by the Company under the Agreement and it may receive up to an additional $220.0 million in development, regulatory and approval milestone payments. However, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.
	The development, regulatory and approval milestones represents non-refundable amounts that would be paid by Janssen to the Company if certain milestones are achieved in the future. The Company has elected to apply the guidance in ASC 605-28 to the milestones. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company's performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.
	The Agreement includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, in general, Janssen is responsible for approximately 60% of collaboration development costs and the Company is responsible for the remaining 40% of collaboration development costs. Generally, costs associated with commercialization will be included in determining pre-tax commercial profits or pre-tax commercial losses, which are to be shared 50% by the Company and 50% by Janssen.
	The collaboration with Janssen provides the Company with an annual cap of its share of IMBRUVICA related research and development expenses and selling, general and administrative expenses, offset by pre-tax commercial profits for each calendar year. In the event that the Company's share of aggregate development costs in any given calendar year, together with any other amounts that become due from the Company, plus the Company's share of pre-tax commercial losses for any calendar quarter in such calendar year, less the Company's share of pre-tax commercial profits for any calendar quarter in such calendar year, exceeds $50.0 million, then amounts that are in excess of $50.0 million (Excess Amounts) are funded by Janssen. Under the Agreement, the total Excess Amounts plus interest may not exceed $225.0 million at any given time.  Interest shall be accrued on the outstanding balance with interest calculated at the average annual European Interbank Offered Rate (EURIBOR) for the EURO or average annual London Interbank Offered Rate (LIBOR) for U.S. Dollars as reported in the Wall Street Journal, plus 2%, calculated on the number of days from the date on which the Company's payment would be due to Janssen. The interest rate on outstanding Excess Amounts shall not exceed 5% per annum, and the cumulative interest on Excess Amounts shall not in the aggregate exceed $25.0 million.
	In the event the Excess Amounts plus interest reaches a maximum of $225.0 million, the Company shall be responsible for its share of development costs, together with any other amounts that become due from the Company, plus its share of any pre-tax commercial loss beyond such maximum. For all calendar quarters following the Company's third profitable calendar quarter for the collaboration, as determined in the Agreement, the Company can no longer add to Excess Amounts and shall be responsible for its own share of development costs along with its share of pre-tax commercial losses incurred in such quarters. As per the Agreement, a profitable quarter shall mean a full calendar quarter beginning after the first commercial sale of IMBRUVICA in which the combined pre-tax profit or loss for the United States and the License Territory is positive and exceeds the development costs for such calendar quarter.
	Under the Agreement, Excess Amounts will become payable to Janssen, together with interest, in calendar quarters subsequent to the three months ended March 31, 2015, which represented the Company's third profitable quarter for the collaboration. Excess Amounts are expected to become payable in subsequent quarters of profitability for the collaboration until the Excess Amounts and applicable interest has been fully repaid. As per the Agreement, within 30 business days after a change of control, Pharmacyclics shall reimburse Janssen for all outstanding Excess Amounts, together with interest.
	As of March 31, 2015, total Excess Amounts were $139.2 million, which was comprised of the cumulative amount funded by Janssen to date of $134.3 million and interest of $4.9 million.
	The Company recognizes Excess Amounts as a reduction to costs and expenses as the Company's repayment of Excess Amounts to Janssen is contingent and would become payable from the Company's share of pre-tax commercial profits only after the third profitable calendar quarter for the collaboration.
	The Agreement also provides that any net profits from the commercialization of products resulting from the collaboration will be shared 50% by the Company and 50% by Janssen. Janssen has sole responsibility and exclusive rights to commercialize the products in the License Territory. The parties hold joint responsibility and co-exclusive rights to commercialize the products in the U.S., and Pharmacyclics will serve as the lead party in such effort. Janssen is commercializing IMBRUVICA outside the U.S.
	In accordance with ASU No. 2009-13 (and as incorporated into ASC Topic 605-25), the Company identified all of the deliverables at the inception of the Agreement. The significant deliverables were determined to be the license, committee services, development services and commercialization services. The commercialization services represent a contingent deliverable for which there is not a significant incremental discount.
	The Company has determined that the license represents a separate unit of accounting as the license has standalone value apart from the committee and development services because the development, manufacturing and commercialization rights conveyed would permit Janssen to perform all efforts necessary to bring the compound to commercialization and begin selling the drug upon regulatory approval. The Company has also determined that the committee and development services each represent individual units of accounting as they have standalone value from each other.  The Company has determined its best estimate of selling prices for the license unit of accounting based on the income approach as defined in ASC 820-10-35-32. This measurement is based on the value indicated by current estimates about those future amounts and reflects management determined estimates and assumptions. These estimates and assumptions include, but are not limited to, how a market participant would use the license, estimated market opportunity and expected market share and assumed royalty rates that would be paid for sales resulting from products developed using the license, similar arrangements entered into by third parties and entity-specific factors such as the terms of the Company's previous collaborative agreement, the Company's pricing practices and pricing objectives, the likelihood that clinical trials will be successful, the likelihood that regulatory approval will be received and that the products will become commercialized and the markets served. These estimates and assumptions led to an expected future cash flow which was discounted based on estimated weighted average cost of capital of 12% and royalty rates ranging from 30% to 40%. The Company has also determined its best estimate of selling prices for the committee and development services, based on the nature of the services to be performed and estimates of the associated effort as well as estimated market rates for similar services. The arrangement consideration of $150.0 million was allocated to the units of accounting based on the relative selling price method.
	Of the $150.0 million upfront payment received, $70.6 million was allocated to the licenses, $15.0 million to the committee services and $64.4 million to the development services. The Company has recognized license revenue upon execution of the arrangement as the associated unit of accounting had been delivered pursuant to the terms of the Agreement. Since inception, the $15.0 million and $64.4 million allocated to committee and development services, respectively, is being recognized as revenue as the related services are provided over the estimated service periods of 17 years and 9 years, which are equivalent to the estimated remaining life of the underlying technology and the estimated remaining development period, respectively.
	Pre-tax Profit (Loss) Under the Agreement
	On a worldwide basis, Pharmacyclics' share of total pre-tax profit (loss) under the Agreement was calculated as follows:
		Three Months Ended
		March 31,
		2015			2014
	50% of Pharmacyclics' U.S. product revenue, net	$	94,579		$	28,090
	Less: 50% of Pharmacyclics' U.S. cost of goods sold	(8,351		)	(3,055		)
	Pharmacyclics' share of U.S. net product revenue less cost of goods sold	86,228			25,035
	Less: Pharmacyclics' share of U.S. commercial expenses under the Agreement	(15,083		)	(14,593		)
	Pharmacyclics' share of U.S. pre-tax profits from the commercialization of IMBRUVICA under the Agreement	71,145			10,442
	Add: Pharmacyclics' share of ex-U.S. pre-tax commercial profit (loss) under the Agreement (1)	12,525			(3,572		)
	Pharmacyclics' share of worldwide pre-tax profits from the commercialization of IMBRUVICA under the Agreement	83,670			6,870
	Less: Pharmacyclics' share of worldwide R&D expenses under the Agreement	(27,332		)	(24,402		)
	Total pre-tax profit (loss) under the Agreement	$	56,338		$	(17,532	)
	(1) For the three months ended March 31, 2015, the Company's share of ex-U.S. pre-tax commercial profit under the Agreement was classified as alliance revenue, net in the condensed consolidated statements of operations. For the three months ended March 31, 2014, the Company's share of ex-U.S. pre-tax commercial loss under the Agreement was classified within selling, general and administrative expenses in the condensed consolidated statements of operations.
	For the three months ended March 31, 2015 and 2014, the Company's total share of costs under the Agreement did not exceed the $50.0 million annual cap provided for in the Agreement. As such, no Excess Amounts were recorded for the three months ended March 31, 2015 or the three months ended March 31, 2014.
	Collaboration Services and Milestone Revenue
	Total collaboration services and milestone revenue recognized with respect to the Agreement consisted of the following (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Collaboration services and other revenue	$	4,089		$	3,135
	License and milestone revenue	—			60,000
	Total	$	4,089		$	63,135
	Collaboration services and other revenue for the three months ended March 31, 2015 included revenue related to committee and development services under the Agreement and net income from the sale of the Company's product to Janssen. For the three months ended March 31, 2014, collaboration services and other revenue included revenue related to committee and development services under the Agreement.
	For the three months ended March 31, 2014, the Company recognized $60.0 million of milestone revenue under its collaboration agreement with Janssen as a result of the FDA approval of IMBRUVICA as a single agent for the treatment of patients with chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy.
	As of March 31, 2015, total deferred revenue related to committee and development services under the Agreement with Janssen was $43.9 million, of which $32.8 million was included in deferred revenue non-current portion.
	Janssen Collaboration Cost Sharing
	The Company recognized development costs under the collaboration as a component of research and development expense in the condensed consolidated statements of operations. For the three months ended March 31, 2015, the Company recognized certain selling, general and administrative expenses under the collaboration, including marketing costs and patent costs as a component of selling, general and administrative in the condensed consolidated statements of operations. For the three months ended March 31, 2014, the Company recognized certain selling, general and administrative expenses under the collaboration, including marketing costs, patent costs and the Company's share of ex-U.S. IMBRUVICA pre-tax commercial loss as a component of selling, general and administrative in the condensed consolidated statements of operations. Expenses which were charged to the collaboration for the three months ended March 31, 2015 and 2014 are as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Collaboration expenses, unadjusted	$	37,590		$	32,365
	Increase (decrease) for cost sharing	(10,258		)	(7,963		)
	Research and development, net	$	27,332		$	24,402
	Collaboration expenses, unadjusted	$	20,730		$	18,220
	Increase (decrease) for cost sharing	(5,647		)	(55		)
	Selling, general and administrative, net	$	15,083		$	18,165
	As of March 31, 2015, the Company had $24.0 million receivable from Janssen which primarily was related to ex-U.S. commercial profits net of ex-U.S. commercial and research and development costs under the Agreement. As of December 31, 2014, the Company had $27.0 million receivable from Janssen, which consisted primarily of a milestone of $20.0 million, $3.9 million related to material and product sales and $1.7 million related to value added taxes. The receivable from Janssen is included within receivable from collaboration partners on the condensed consolidated balance sheets.
	As of March 31, 2015, the Company had $77.5 million payable to Janssen which primarily consisted of amounts due for Janssen's share of U.S. pre-tax commercial profits. As of December 31, 2014, the Company had $79.8 million payable to Janssen, of which $76.7 million was related to Janssen's share of pre-tax commercial profits, $2.8 million was related to cost-sharing under the Agreement and $0.3 million was related to value added taxes. The payable to Janssen is included within payable to collaboration partner on the condensed consolidated balance sheets.
	Collaboration and License Agreement with Servier
	In April 2009, the Company entered into a collaboration and license agreement with Servier to research, develop and commercialize pan-HDAC compounds, including abexinostat (PCI-24781), which is an orally active, novel, small molecule inhibitor of pan-HDAC enzymes. Under the terms of the agreement, Servier acquired the exclusive right to develop and commercialize the pan-HDAC inhibitor product worldwide except for the United States. In September 2014, the Company concluded its collaboration and license agreement with Servier under which Servier had acquired the exclusive right to develop and commercialize the pan-HDAC inhibitor product worldwide except for the U.S. and its possessions. The Company continued to own all rights within the U.S. The Company and Servier terminated the collaboration and license agreement effective November 23, 2014. Upon the termination of the agreement, Servier’s rights to ex-U.S. development and commercialization of the Company's pan-HDAC inhibitor compounds were returned to Pharmacyclics, giving the Company full global development and commercialization rights.
	Total revenue recognized with respect to the Company's collaboration and license agreement with Servier for the three months ended March 31, 2014 was $0.1 million.
	License agreement with Novo Nordisk A/S
	In October 2012, the Company entered into a license agreement with Novo Nordisk A/S (Novo Nordisk). Under the terms of the agreement, Novo Nordisk acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, as an excipient in a product containing a Novo Nordisk active pharmaceutical ingredient for a restricted disease indication outside of oncology. Novo Nordisk will utilize PCI-27483 as an excipient in a product within Novo Nordisk's biopharmaceutical unit. Novo Nordisk is solely responsible for all further research and development activities within the restricted disease indication outside of oncology.
	In connection with entering into the license agreement with Novo Nordisk, the Company received an upfront payment of $5.0 million in October 2012. In addition, the Company may receive up to $55.0 million based on the achievement of certain development, regulatory and sales milestones. Upon commercialization, the Company will also receive low single digit tiered royalties on Novo Nordisk's net sales of biopharmaceutical formulations utilizing the addition of PCI-27483.
	On June 28, 2013, the Company entered into an amended and restated license agreement with Novo Nordisk to expand the scope of the license granted by the Company to Novo Nordisk in October 2012. Under the amended and restated license agreement with Novo Nordisk, the Company has no additional obligations related to the delivery of the license. Under the amended and restated license agreement, upon a Pharmacyclics change of control, Novo Nordisk may, in its sole discretion, terminate or suspend all development reporting obligations of Novo Nordisk to Pharmacyclics.
The Company recognized no revenue related to the Novo Nordisk agreement for three months ended March 31, 2015 and the three months ended March 31, 2014.
Celera Corporation
In April 2006, the Company acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Genomics, an Applera Corporation business (now Celera Corporation - a subsidiary of Quest Diagnostics Incorporated). Future milestone payments under the agreement, as amended, could total as much as approximately $97.0 million, although the Company currently cannot predict if or when any of the milestones will be achieved. Approximately two-thirds of the milestone payments relate to the Company's HDAC inhibitor program and approximately one-third relates to the Company's Factor VIIa inhibitor program. Approximately 90% of the potential future milestone payments would be paid to Celera after obtaining regulatory approval in various countries. To date, no milestone payments have been triggered related to the Company's HDAC inhibitor or Factor VIIa programs.
In addition to the milestone payments, the Company is required to make single-digit royalty payments based on annual sales of IMBRUVICA and would be required to make single-digit royalty payments based on annual sales of drugs commercialized from the Company's HDAC inhibitor, Factor VIIa inhibitor and certain other BTK inhibitor programs. For the three months ended March 31, 2015 and 2014, the Company recognized royalty expense under the Celera agreement of approximately $11.8 million and $3.9 million, respectively, on net product sales of IMBRUVICA in the United States. Royalty expense related to net product sales of IMBRUVICA is included within cost of goods sold in the condensed consolidated statement of operations.
For any BTK inhibitor product or Factor VIIa inhibitor product obtained from Celera, the agreement with Celera expires on a product-by-product and country-by-country basis. The term of the agreement for a given BTK inhibitor product or Factor VIIa inhibitor product shall expire in a given country upon the expiration of the last-to-expire Celera patent assigned to the Company that covers the manufacture, use, sale, offer for sale, or importation of such product in such country. For any HDAC inhibitor product obtained from Celera, the agreement with Celera expires on a product-by-product and country-by-country basis. The term of the agreement for a given HDAC inhibitor product shall expire in a given country upon the expiration of the last-to-expire Celera patent assigned to the Company that covers the sale of such product in such country.
The Company may terminate the agreement with Celera in its entirety, or with respect to one or more of the three classes of products (BTK inhibitor products, HDAC inhibitor products and Factor VIIa inhibitor products) obtained from Celera, at any time by giving Celera at least 60 days' prior written notice. If the Company terminates the agreement with respect to a particular class of products, ownership of the Celera intellectual property assigned to the Company relating to the products in the terminated product class will revert to Celera. If the Company terminates the agreement in its entirety, ownership of all of the Celera intellectual property assigned to the Company will revert to Celera.
The agreement with Celera may be terminated effective immediately upon a party's written notice to the other party for a breach by the other party that remains uncured for 90 days after notice of the breach is given to the breaching party. If the Company breaches the agreement only with respect to one or two of the three classes of products obtained from Celera, but not with respect to all three classes of products, and if the Company's breach remains uncured for 90 days after the Company has received notice of breach from Celera, Celera may terminate the agreement solely with respect to the class or classes of products affected by the Company's breach, but may not terminate the agreement with respect to the class or classes of products unaffected by the Company's breach.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory
	Inventories consist of raw materials, work-in-process and finished goods related to the production of IMBRUVICA. Raw materials include ibrutinib active pharmaceutical ingredient (API). Work-in-process includes third-party manufacturing and associated labor costs relating to the Company’s personnel involved in the production process. Included in inventories are raw materials and work-in-process that may be used as clinical products, which are charged to research and development expense when the product enters the research and development process.
	The components of inventory are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	15,415	$	—
	Work-in-process	26,730		27,591
	Finished goods	6,880		6,855
		$	49,025	$	34,446
	The Company records cash advances that it pays prior to the receipt of inventory as advances to manufacturers in the condensed consolidated balance sheets. The cash advances may be forfeited if the Company terminates the scheduled production. The Company expects the carrying value of the advances to manufacturers to be fully realized.

Fair_Value_Measurements_and_Ma

Fair Value Measurements and Marketable Securities	3 Months Ended
	Mar. 31, 2015
Assets, Fair Value Disclosure [Abstract]
Fair Value Measurements and Marketable Securities	Fair Value Measurements and Marketable Securities
	The Company's marketable securities are classified as “available-for-sale.” The Company includes these investments in current assets and carries them at fair value. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss on the condensed consolidated balance sheets. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income in the condensed consolidated statements of operations. Gains and losses on securities sold are recorded based on the specific identification method and are included in interest and other income, net in the condensed consolidated statements of operations. The Company records all investment purchases and sales based on the trade date.
	Management assesses whether declines in the fair value of marketable securities are other than temporary. If the decline is judged to be other than temporary, the cost basis of the individual security is written down to fair value and the amount of the write down is included in the statement of operations. In determining whether a decline is other than temporary, management considers various factors including the length of time and the extent to which the market value has been less than cost, the financial condition and near-term prospects of the issuer and the Company's intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.
	The fair value of the Company's financial assets and liabilities is determined by using three levels of input which are defined as follows:
	Level 1 - Quoted prices in active markets for identical assets or liabilities. At March 31, 2015, the Company's Level 1 assets were comprised of money market funds.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company's short-term investments primarily utilize broker quotes in markets with infrequent transactions for valuation of these securities. At March 31, 2015, the Company's Level 2 assets were comprised of FDIC insured certificates of deposit.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. At March 31, 2015, the Company did not hold any Level 3 assets.
	The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
	The following is a summary of the Company's available-for-sale securities at March 31, 2015 and December 31, 2014, respectively (in thousands):
	As of March 31, 2015		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	Certificates of deposit – FDIC insured		$	11,960		$	—		$	(2	)		$	11,958
	Total marketable securities		$	11,960		$	—		$	(2	)		$	11,958
	As of December 31, 2014		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	Certificates of deposit – FDIC insured		$	11,960		$	—		$	(8	)		$	11,952
	Total marketable securities		$	11,960		$	—		$	(8	)		$	11,952
	At March 31, 2015, the Company's marketable securities had the following remaining contractual maturities (in thousands):
		Amortized Cost			Estimated Fair Value
	Less than one year	$	11,960		$	11,958
	The following table sets forth the basis of fair value measurements for the Company's cash equivalents and available-for-sale securities as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	Money market funds	$	376,585		$	—		$	—			$	376,585
	Marketable securities:
	Certificates of deposit - FDIC insured	—			11,958			—				11,958
		$	376,585		$	11,958		$	—			$	388,543
		31-Dec-14
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	Money market funds	$	373,119		$	—		$	—			$	373,119
	Marketable securities:
	Certificates of deposit - FDIC insured	—			11,952			—				11,952
		$	373,119		$	11,952		$	—			$	385,071
	There were no transfers between levels of the fair value hierarchy during the three months ended March 31, 2015.

Balance_Sheet_Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	Balance Sheet Components
	Property and equipment, net, consists of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Equipment	$	20,075		$	13,363
	Leasehold improvements	21,677			9,951
	Furniture and fixtures	1,278			1,278
	Construction in progress	1,691			19,461
		44,721			44,053
	Less: Accumulated depreciation and amortization	(12,580		)	(11,577		)
		$	32,141		$	32,476
	Accrued liabilities consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Accrued discounts and rebates	$	25,463		$	18,125
	Accrued payroll and employee related expenses	19,941			19,645
	Accrued clinical related	17,461			14,806
	Accrued royalty to Celera (see Note 3)	14,924			10,646
	Accrued outside services	7,254			5,114
	Accrued value added taxes	1,357			7,395
	Accrued contract manufacturing	1,355			2,380
	Accrued other	7,684			10,168
		$	95,439		$	88,279
	Deferred revenue consists of the following (in thousands):
	Current portion:	March 31,			December 31,
		2015			2014
	Deferred revenue related to the Agreement (see Note 3)	$	11,172		$	11,656
	Deferred revenue from sales to collaboration partner	7,625			7,117
		$	18,797		$	18,773
	Non-current portion:	March 31,			December 31,
		2015			2014
	Deferred revenue related to the Agreement (see Note 3)	$	32,757		$	34,885

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets
	On April 15, 2014, the Company entered into an agreement with a third party to acquire technology assets in the amount of $9.3 million in cash. The Company is amortizing the technology assets over an estimated life of 13 years which reflects the estimated remaining useful life of the technology assets. Amortization expense was $0.2 million for the three months ended March 31, 2015. Accumulated amortization as of March 31, 2015 was $0.7 million.
	The following table presents the Company's estimate of amortization expense for the remainder of 2015 and the succeeding five fiscal years (in thousands):
	Fiscal Year	Future Amortization of Intangible Assets
	2015 (remaining 9 months)	$	548
	2016	728
	2017	728
	2018	728
	2019	728
	2020	728
	Thereafter	4,362
	Total	$	8,550

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The income tax provision includes U.S. federal, state and local, and foreign income taxes and is based on the application of a forecasted annual income tax rate applied to the year-to-date pre-tax income (loss). In determining the estimated annual effective income tax rate, the Company analyzes various factors including projections of its annual earnings, the tax jurisdictions in which the earnings will be generated, the impact of state and local income taxes, its ability to use tax credits and net operating loss carryforwards and available tax planning alternatives. Discrete items including the effect of changes in tax laws, tax rates and certain circumstances with respect to valuation allowances or other unusual or non-recurring tax adjustments are reflected in the period in which they occur.
	For the three months ended March 31, 2015, the Company recorded an income tax expense of less than $0.1 million, compared to an income tax benefit of less than $0.1 million for the three months ended March 31, 2014. The difference between the estimated annual effective tax rate and the federal statutory rate of 35% was primarily attributable to a year to date benefit not expected to be realized under the application of the ASC No. 740-270, Income tax - Interim reporting (previously FIN 18, “Accounting for Income Taxes in Interim Period”). For the three months ended March 31, 2015, no tax benefit has been recorded under an effective tax rate method as no benefit is expected to be realized for the current year given the Company's full valuation allowance position and also based on the Company's estimate of a tax provision for the year ending December 31, 2015. For the three months ended March 31, 2015, the income tax provision was related to discrete items recorded in the period.
	The Company recorded a full valuation allowance against all of its net deferred tax assets at both March 31, 2015 and December 31, 2014. The Company intends to continue maintaining a full valuation allowance on its deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. However, should there be greater market demand for or greater market acceptance of IMBRUVICA than management has currently forecasted, there is a reasonable possibility that within the next year sufficient positive evidence may become available to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. As such, the Company may release a significant portion of its valuation allowance against its deferred tax assets within the next 12 months. This release would result in the recognition of certain deferred tax assets and a decrease to income tax expense for the period such release is recorded.
	The total amount of the unrecognized tax benefits if recognized would be an adjustment to the amount of deferred tax assets reported. The Company may from time to time be assessed interest or penalties by major tax jurisdictions, although there have been no material assessments. In the event the Company receives an assessment for interest and/or penalties, it would be classified in the financial statements as income tax expense. As of March 31, 2015, all tax years in the U.S. remain open due to the taxing authorities' ability to adjust operating loss carry forwards. The Company does not expect any material changes to the unrecognized tax benefits reported above during the next 12 months. The Company is unable to make a reasonable estimate as to when cash settlements with the relevant taxing authorities will occur.
	During the year ended December 31, 2013, the Company was notified by the Internal Revenue Service (IRS) that it will be audited for the tax years ended June 30, 2012 and 2011. As of March 31, 2015, no material adjustments have been proposed by the IRS.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Facilities Lease
	As of March 31, 2015, the Company leases 168,189 square feet for its corporate headquarters in Sunnyvale, California. Of this total space, 79,776 square feet are leased under an operating lease that expires in November 2017, with an option to extend the lease term for an additional five years. An additional 52,400 square feet are leased under an operating lease which expires in February 2023, which provides for an option to early terminate the lease in 2018 and an option to extend the lease term for an additional five years. In January 2015, the Company entered into a lease agreement for additional office space for its corporate headquarters in Sunnyvale, California for approximately 36,000 square feet with annual rental expense of $0.5 million under an operating lease that expires in May 2016. In addition, the Company leases approximately 8,000 square feet for its Pharmacyclics Switzerland GmbH office under an agreement that expires in May 2015 and approximately 7,000 square feet of office space in South San Francisco, California under an agreement that expires in May 2015. In February 2015, the Company entered into a lease agreement for approximately 10,000 square feet of office space in South San Francisco, California, with annual rental expense of $0.4 million under an operating lease, expiring in February 2017.
	The Company recognizes rental expense on the facilities on a straight-line basis over the lease term. Differences between the straight line rent expense and rent payments are classified as deferred rent liability on the balance sheet. As of March 31, 2015, the Company's future minimum lease payments under non-cancelable operating leases are as follows (in thousands):
	Fiscal year	Operating Lease Commitments
	2015 (remaining 9 months)	$	2,376
	2016	2,752
	2017	2,143
	2018	857
	2019	882
	2020	909
	Thereafter	1,981
	Total	$	11,900
	Purchase Commitments
	The Company had non-cancelable purchase obligations for approximately $76.8 million and $85.9 million as of March 31, 2015 and December 31, 2014, respectively.
	Excess Amounts under collaboration and license agreement with Janssen
	Under the Agreement, Excess Amounts will become payable to Janssen, together with interest, in calendar quarters subsequent to the three months ended March 31, 2015, which represented the Company's third profitable quarter for the collaboration. Excess Amounts are expected to become payable in subsequent quarters of profitability for the collaboration until the Excess Amounts and applicable interest has been fully repaid. As of March 31, 2015, total Excess Amounts were $139.2 million (which was comprised of the cumulative amount funded by Janssen to-date of $134.3 million and interest of $4.9 million).
	Legal Proceedings
	The Company is involved in various claims and legal proceedings, including the class actions suits described below. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. These accruals are adjusted periodically as assessments change or additional information becomes available. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s condensed consolidated financial position, results of operations or cash flows.
	In March 2015, four putative class action lawsuits were filed against the members of the Pharmacyclics board of directors and certain others (the Defendants) in the Superior Court of the State of California, Santa Clara County. Each alleges generally that the members of the Pharmacyclics board of directors breached their fiduciary duties in connection with AbbVie's offer to acquire all of the outstanding shares of Pharmacyclics and the Mergers by, among other things, (i) failing to maximize the value of Pharmacyclics to its public stockholders, (ii) ignoring or failing to protect against conflicts of interests and (iii) agreeing to unreasonable deal protection devices (see Note 14 for a brief discussion of AbbVie's offer and the Mergers). The plaintiffs seek, among other relief, equitable relief to enjoin consummation of the offer and the Mergers, rescission of the offer and the Mergers and/or rescissory damages, and attorneys' fees and costs.
	On April 16, 2015, all parties to the shareholder suits entered into a Memorandum of Understanding ("MOU") to settle these lawsuits. The Defendants in the MOU have denied, and continue to deny, that any of them has committed, threatened to commit, or aided and abetted in the commission of, any wrongdoing, violations of law or breaches of duty to the plaintiffs, the class or anyone else in connection with the settled claims. The Company currently anticipates that the MOU will undergo judicial review for approval during the second half of 2015.

Basic_and_Diluted_Net_Income_P

Basic and Diluted Net Income Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Basic and Diluted Net Income Per Share	Basic and Diluted Net Income Per Share
	Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding stock options, including performance-based stock options and restricted stock units for which performance criteria have been achieved, restricted stock units with time-based vesting and shares to be purchased under the employee stock purchase plan. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company's common stock can result in a greater dilutive effect from potentially dilutive securities.
	The computations of basic and diluted net income per share are as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income	$	4,147	$	18,275
	Denominator:
	Weighted average common shares - basic	76,205		74,754
	Effect of dilutive securities:
	Employee stock options	2,806		3,306
	Employee stock purchase plan	95		4
	Restricted stock units	125		—
	Weighted average common shares - diluted	79,231		78,064
	Net income per share:
	Basic	$	0.05	$	0.24
	Diluted	$	0.05	$	0.23
	Potentially dilutive securities excluded from net income per share - diluted because their effect is anti-dilutive	43		658

StockBased_Compensation_and_St

Stock-Based Compensation and Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Share-Based Compensation and Stockholders' Equity	Stock-Based Compensation and Stockholders’ Equity
	Stock Plans
	At the Company's annual meeting of stockholders on May 8, 2014, the Company's stockholders approved the 2014 Equity Incentive Award Plan (2014 Plan). The 2014 Plan replaced the Company's expiring 2004 Equity Incentive Award Plan (2004 Plan). The 2014 Plan provides for the issuance of various forms of awards including among others, incentive and non-qualified stock options and restricted stock units.
	Stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Cost of goods sold	$	425		$	417
	Research and development	10,432			5,535
	Selling, general and administrative	12,639			7,034
	Total stock-based compensation	$	23,496		$	12,986
	The following table summarizes the Company's stock option activity for the three months ended March 31, 2015 (in thousands, except per share amounts):
		Number		Weighted
		of		Average
		Shares		Exercise
				Price per Share
	Balance at December 31, 2014	4,200		$	43.5
	Exercised	(855	)	21.45
	Granted	400		80.78
	Forfeited	(35	)	92.03
	Balance at March 31, 2015	3,710		$	52.13
	The following table summarizes all of the Company's restricted stock unit activity for the three months ended March 31, 2015 (in thousands, except per share amounts):
		Shares		Weighted Average Grant Date Fair Value
	Balance at December 31, 2014	188		$	115.32
	Granted	174		159.26
	Released	(6	)	135.51
	Forfeited	(4	)	100.42
	Balance at March 31, 2015	352		$	136.82
	The accounting grant date for employee stock options and restricted stock units with performance obligations is the date on which the performance goals have been defined and a mutual understanding of the terms has been reached. The Company's time-based stock option awards and restricted stock units typically vest over a four-year period subject to the employee’s continued service. The Company's performance-based stock options granted to executive officers typically vest over a four-year period. The Company's performance-based RSUs granted to executive officers generally vest over a period of one to five years. The vesting of the Company's performance-based stock options and RSUs is subject to the satisfaction of performance criteria established annually for such executive as determined by the Compensation Committee after reviewing the performance reports. The tables above exclude 0.4 million performance stock options and less than 0.1 million of performance based restricted stock units granted in current and prior fiscal years for which the performance criteria had not been established as of March 31, 2015.
	At March 31, 2015, 1.8 million shares were available for grant under the 2014 Plan.
	There were no sales under the Employee Stock Purchase Plan (ESPP) during the three months ended March 31, 2015 and 2014. Shares available for future purchase under the ESPP were 0.5 million at March 31, 2015.
	Additional paid-in capital increased by $59.3 million during the three months ended March 31, 2015 as a result of stock-based compensation of $23.6 million, the issuance of common stock upon the exercise of stock options of $18.3 million, the excess tax benefit from stock-based compensation arrangements of $18.0 million, which was partially offset by a $0.6 million reduction for tax payments related to shares withheld for vested RSUs.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	Kenneth A. Clark, a director of the Company since November 2012, is a member of the law firm of Wilson Sonsini Goodrich & Rosati (WSGR). The Company retains WSGR as legal counsel for various matters, primarily consisting of intellectual property matters and matters related to the pending Mergers with AbbVie, Inc. (see Note 14 for a brief discussion of the Mergers). During the three months ended March 31, 2015 and 2014, the Company made payments to WSGR of $0.9 million and $0.8 million, respectively. As of March 31, 2015 and December 31, 2014, $3.4 million and $1.3 million, respectively, was included in accrued liabilities in the condensed consolidated balance sheets for amounts due to WSGR.
	In January 2015, the Company entered into a six month consulting services agreement with Dr. Robert Booth, a member of its Board of Directors (the Consulting Agreement). In addition, on January 22, 2015, Dr. Booth was granted 10,000 RSUs which vest over four years. The grant date fair value of the RSUs was $1.6 million based on the Company’s closing stock price on January 22, 2015. The Consulting Agreement provides for maximum payments to Dr. Booth of $0.1 million over the six month term and for the reimbursement of documented, authorized travel and out-of-pocket expenses. There were no payments made to Dr. Booth under the Consulting Agreement during the three months ended March 31, 2015.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2014, the FASB issued ASU No. 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity", or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. ASU 2014-08 is effective for fiscal and interim periods beginning on or after December 15, 2014, with early adoption permitted. The Company has adopted this new guidance which resulted in no impact on its consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which provides guidance for revenue recognition. This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This standard is effective for annual and interim reporting periods beginning after December 15, 2016. Early adoption is not permitted. The Company is currently evaluating the impact of the adoption of this accounting standard on its consolidated financial statements.
	In June 2014, the FASB issued ASU 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period." ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. This new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this accounting standard on its consolidated financial statements.
	In August 2014, the FASB issued ASU No. 2014-15: “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” This standard requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016.  This standard is not expected to have any impact on current disclosures in the financial statements.

Pending_Agreement_and_Plan_of_

Pending Agreement and Plan of Reorganization with AbbVie Inc.	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Pending Agreement and Plan of Reorganization with AbbVie Inc.	Pending Agreement and Plan of Reorganization with AbbVie Inc.
	On March 4, 2015, the Company entered into an Agreement and Plan of Reorganization (the "Merger Agreement") with AbbVie Inc., a Delaware corporation (“AbbVie”), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie (“Purchaser”) and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie (“Merger Sub 2” and, together with Purchaser, the “Merger Subs”).
	Pursuant to the Merger Agreement, the Purchaser commenced a tender offer (the “Offer”) to purchase all of the Company's outstanding shares of common stock. Each share of the Company's common stock accepted by Purchaser in the Offer will be exchanged for the right to receive, at the election of each of the Company's stockholders, and subject to proration as described in the Merger Agreement:
	•	$261.25 in cash; or
	•	$261.25 worth of shares of common stock of AbbVie Inc.; or
	•	$152.25 in cash and $109.00 worth of shares of common stock of AbbVie Inc.
	The shares of AbbVie common stock to be issued will be valued at the 10-day volume weighted average sale price per share of AbbVie common stock for the ten trading days prior to the acceptance of the shares in the Offer as further described in the Merger Agreement and amendment thereto.
	If the Offer is consummated, Purchaser will be merged into the Company, followed by a merger of the Company into Merger Sub 2 (the “Mergers”). All outstanding shares of the Company’s common stock which were not validly tendered in the Offer will be converted into the right to receive, at the election of each holder of such shares, and subject to proration as described in the Merger Agreement, the same consideration as set forth above.
	The transaction is valued at approximately $21 billion, including consideration for settlement of the Company’s outstanding stock options and restricted stock units pursuant to the terms and conditions of the Merger Agreement.
	The Merger Agreement contains certain termination rights for both the Company and AbbVie and further provides that the Company must pay AbbVie a termination fee of $680.0 million in cash upon termination of the Merger Agreement under specified circumstances. Furthermore, in connection with the entry into the Merger Agreement, the Company adopted the following: (i) a severance plan for each of its employees and (ii) amendments to its 2004 Plan and 2014 Plan, in accordance with the terms of the Merger Agreement.
	The Merger Agreement and the consummation of the transactions contemplated thereby have been unanimously approved by the Company's board of directors, which has recommended that the Company's stockholders accept the Offer and tender their shares of the Company's common stock to Purchaser pursuant to the Offer.

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event
	On May 1, 2015, AbbVie announced that it has extended the expiration of the Offer (see Note 14) to 5 p.m., New York City time, on May 15, 2015. All other terms and conditions of the Offer remain unchanged.

The_Company_and_Significant_Ac1

The Company and Significant Accounting Policies - (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Pharmacyclics, Inc. and its wholly-owned subsidiaries, Pharmacyclics (Europe) Limited, Pharmacyclics Switzerland GmbH, Pharmacyclics Cayman Ltd. and Pharmacyclics (Shanghai) Management Consulting Service Limited. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations.
	The interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with Article 10 of Regulation S-X which governs quarterly reporting and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of the Company's financial position, results of operations and cash flows in accordance with United States generally accepted accounting principles (GAAP). The December 31, 2014 condensed consolidated balance sheet data contained within this Form 10-Q was derived from audited consolidated financial statements included in the Company's Form 10-K for the year ended December 31, 2014, but does not include all disclosures required by accounting principles generally accepted in the United States.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all normal and recurring adjustments necessary for a fair statement of the results of operations, financial position and cash flows. These condensed consolidated financial statements should be read in conjunction with the financial statements included in the Company's Form 10-K for the year ended December 31, 2014. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in the Company's condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
Concentration of credit risk	Concentration of credit risk
	Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, marketable securities, accounts receivable and the receivable from collaboration partners. The Company places its cash and cash equivalents with high-credit quality financial institutions and invests in debt instruments of financial institutions, corporations and government entities with strong credit ratings. The Company's management believes it has established guidelines relative to credit quality, diversification and maturities that maintain safety and liquidity.
	The Company sells IMBRUVICA to some customers who have in-house dispensing capabilities, specialty pharmacies (SP) that sell to individual patients, specialty distributors (SD) that sell to hospital pharmacies and other organizations that we have contracted with. The Company continuously monitors the creditworthiness of its customers and has internal policies regarding customer credit limits. The Company's policy is to estimate the allowance for doubtful accounts based on the credit worthiness of its customers, historical payment patterns, the aging of accounts receivable balances and general economic conditions. As of March 31, 2015 and December 31, 2014, the Company had no significant allowance for doubtful accounts. As of March 31, 2015, four individual customers accounted for 22%, 20%, 19% and 18% of gross accounts receivable. As of December 31, 2014, four individual customers accounted for 25%, 22%, 19% and 15% of gross accounts receivable.

Product_Revenue_Net_Tables

Product Revenue, Net - (Tables)	3 Months Ended
	Mar. 31, 2015
Revenues [Abstract]
Schedule of Provisions, Credits and Payments	The following table summarizes the provisions, and credits/payments, for product revenue, net of adjustments (in thousands):
		Total
	Balance as of December 31, 2014	$	26,735
	Provision related to current period product revenue	28,779
	Credits/payments	(20,972		)
	Balance as of March 31, 2015	$	34,542
		Total
	Balance as of December 31, 2013	$	1,206
	Provision related to current period product revenue	8,639
	Credits/payments	(2,095		)
	Balance as of March 31, 2014	$	7,750
Schedule of Customers Who Represent 10% or More of the Company's Revenue	The following table sets forth customers who represented 10% or more of the Company's product revenue, net for the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
	Customer	2015			2014
	A	29	%		29	%
	B	21	%		19	%
	C	16	%		12	%
	D	13	%		8	%
	E	10	%		13	%

Collaboration_and_Other_Agreem1

Collaboration and Other Agreements - (Tables)	3 Months Ended
	Mar. 31, 2015
Collaboration and Other Agreements [Abstract]
Schedule of Revenue Related to Collaboration and License Arrangements	Total collaboration services and milestone revenue recognized with respect to the Agreement consisted of the following (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Collaboration services and other revenue	$	4,089		$	3,135
	License and milestone revenue	—			60,000
	Total	$	4,089		$	63,135
	On a worldwide basis, Pharmacyclics' share of total pre-tax profit (loss) under the Agreement was calculated as follows:
		Three Months Ended
		March 31,
		2015			2014
	50% of Pharmacyclics' U.S. product revenue, net	$	94,579		$	28,090
	Less: 50% of Pharmacyclics' U.S. cost of goods sold	(8,351		)	(3,055		)
	Pharmacyclics' share of U.S. net product revenue less cost of goods sold	86,228			25,035
	Less: Pharmacyclics' share of U.S. commercial expenses under the Agreement	(15,083		)	(14,593		)
	Pharmacyclics' share of U.S. pre-tax profits from the commercialization of IMBRUVICA under the Agreement	71,145			10,442
	Add: Pharmacyclics' share of ex-U.S. pre-tax commercial profit (loss) under the Agreement (1)	12,525			(3,572		)
	Pharmacyclics' share of worldwide pre-tax profits from the commercialization of IMBRUVICA under the Agreement	83,670			6,870
	Less: Pharmacyclics' share of worldwide R&D expenses under the Agreement	(27,332		)	(24,402		)
	Total pre-tax profit (loss) under the Agreement	$	56,338		$	(17,532	)
	(1) For the three months ended March 31, 2015, the Company's share of ex-U.S. pre-tax commercial profit under the Agreement was classified as alliance revenue, net in the condensed consolidated statements of operations. For the three months ended March 31, 2014, the Company's share of ex-U.S. pre-tax commercial loss under the Agreement was classified within selling, general and administrative expenses in the condensed consolidated statements of operations.
Schedule of Collaborative Arrangements, Recognized Costs	Expenses which were charged to the collaboration for the three months ended March 31, 2015 and 2014 are as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Collaboration expenses, unadjusted	$	37,590		$	32,365
	Increase (decrease) for cost sharing	(10,258		)	(7,963		)
	Research and development, net	$	27,332		$	24,402
	Collaboration expenses, unadjusted	$	20,730		$	18,220
	Increase (decrease) for cost sharing	(5,647		)	(55		)
	Selling, general and administrative, net	$	15,083		$	18,165

Inventory_Tables

Inventory - (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventory are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	15,415	$	—
	Work-in-process	26,730		27,591
	Finished goods	6,880		6,855
		$	49,025	$	34,446

Fair_Value_Measurements_and_Ma1

Fair Value Measurements and Marketable Securities - (Tables)	3 Months Ended
	Mar. 31, 2015
Assets, Fair Value Disclosure [Abstract]
Available-For-Sale Securities Reconciliation	The following is a summary of the Company's available-for-sale securities at March 31, 2015 and December 31, 2014, respectively (in thousands):
	As of March 31, 2015		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	Certificates of deposit – FDIC insured		$	11,960		$	—		$	(2	)		$	11,958
	Total marketable securities		$	11,960		$	—		$	(2	)		$	11,958
	As of December 31, 2014		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	Certificates of deposit – FDIC insured		$	11,960		$	—		$	(8	)		$	11,952
	Total marketable securities		$	11,960		$	—		$	(8	)		$	11,952
Remaining Contractual Maturities on Marketable Securities	At March 31, 2015, the Company's marketable securities had the following remaining contractual maturities (in thousands):
		Amortized Cost			Estimated Fair Value
	Less than one year	$	11,960		$	11,958
Basis of Fair Value Measurements for Available-For-Sale Securities	The following table sets forth the basis of fair value measurements for the Company's cash equivalents and available-for-sale securities as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31, 2015
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	Money market funds	$	376,585		$	—		$	—			$	376,585
	Marketable securities:
	Certificates of deposit - FDIC insured	—			11,958			—				11,958
		$	376,585		$	11,958		$	—			$	388,543
		31-Dec-14
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	Money market funds	$	373,119		$	—		$	—			$	373,119
	Marketable securities:
	Certificates of deposit - FDIC insured	—			11,952			—				11,952
		$	373,119		$	11,952		$	—			$	385,071

Balance_Sheet_Components_Table

Balance Sheet Components - (Tables)	3 Months Ended
	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Schedule of Property Plant and Equipment	Property and equipment, net, consists of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Equipment	$	20,075		$	13,363
	Leasehold improvements	21,677			9,951
	Furniture and fixtures	1,278			1,278
	Construction in progress	1,691			19,461
		44,721			44,053
	Less: Accumulated depreciation and amortization	(12,580		)	(11,577		)
		$	32,141		$	32,476
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Accrued discounts and rebates	$	25,463		$	18,125
	Accrued payroll and employee related expenses	19,941			19,645
	Accrued clinical related	17,461			14,806
	Accrued royalty to Celera (see Note 3)	14,924			10,646
	Accrued outside services	7,254			5,114
	Accrued value added taxes	1,357			7,395
	Accrued contract manufacturing	1,355			2,380
	Accrued other	7,684			10,168
		$	95,439		$	88,279
Deferred Revenue	Deferred revenue consists of the following (in thousands):
	Current portion:	March 31,			December 31,
		2015			2014
	Deferred revenue related to the Agreement (see Note 3)	$	11,172		$	11,656
	Deferred revenue from sales to collaboration partner	7,625			7,117
		$	18,797		$	18,773
	Non-current portion:	March 31,			December 31,
		2015			2014
	Deferred revenue related to the Agreement (see Note 3)	$	32,757		$	34,885

Intangible_Assets_Tables

Intangible Assets - (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived Intangible Assets Amortization Expense	The following table presents the Company's estimate of amortization expense for the remainder of 2015 and the succeeding five fiscal years (in thousands):
	Fiscal Year	Future Amortization of Intangible Assets
	2015 (remaining 9 months)	$	548
	2016	728
	2017	728
	2018	728
	2019	728
	2020	728
	Thereafter	4,362
	Total	$	8,550

Commitments_and_Contingencies_

Commitments and Contingencies - (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	As of March 31, 2015, the Company's future minimum lease payments under non-cancelable operating leases are as follows (in thousands):
	Fiscal year	Operating Lease Commitments
	2015 (remaining 9 months)	$	2,376
	2016	2,752
	2017	2,143
	2018	857
	2019	882
	2020	909
	Thereafter	1,981
	Total	$	11,900

Basic_and_Diluted_Net_Income_P1

Basic and Diluted Net Income Per Share - (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Computation of Basic and Diluted Net Income Per Share	The computations of basic and diluted net income per share are as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income	$	4,147	$	18,275
	Denominator:
	Weighted average common shares - basic	76,205		74,754
	Effect of dilutive securities:
	Employee stock options	2,806		3,306
	Employee stock purchase plan	95		4
	Restricted stock units	125		—
	Weighted average common shares - diluted	79,231		78,064
	Net income per share:
	Basic	$	0.05	$	0.24
	Diluted	$	0.05	$	0.23
	Potentially dilutive securities excluded from net income per share - diluted because their effect is anti-dilutive	43		658

StockBased_Compensation_and_St1

Stock-Based Compensation and Stockholders' Equity - (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Share-based Compensation Recognized in Statements of Operations	Stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Cost of goods sold	$	425		$	417
	Research and development	10,432			5,535
	Selling, general and administrative	12,639			7,034
	Total stock-based compensation	$	23,496		$	12,986
Stock Option Activity	The following table summarizes the Company's stock option activity for the three months ended March 31, 2015 (in thousands, except per share amounts):
		Number		Weighted
		of		Average
		Shares		Exercise
				Price per Share
	Balance at December 31, 2014	4,200		$	43.5
	Exercised	(855	)	21.45
	Granted	400		80.78
	Forfeited	(35	)	92.03
	Balance at March 31, 2015	3,710		$	52.13
Restricted Stock Units Activity	The following table summarizes all of the Company's restricted stock unit activity for the three months ended March 31, 2015 (in thousands, except per share amounts):
		Shares		Weighted Average Grant Date Fair Value
	Balance at December 31, 2014	188		$	115.32
	Granted	174		159.26
	Released	(6	)	135.51
	Forfeited	(4	)	100.42
	Balance at March 31, 2015	352		$	136.82

The_Company_and_Significant_Ac2

The Company and Significant Accounting Policies - (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of Countries in which Pharmaceutical is Approved	47
Number of Countries within the European Union in which Pharmaceutical is Approved	28
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of customers that counted for more than 10% of accounts receivable	4	4
Customer Concentration Risk [Member] | Customer One [Member] | Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Customer percentage of accounts receivable	22.00%	25.00%
Customer Concentration Risk [Member] | Customer Two [Member] | Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Customer percentage of accounts receivable	20.00%	22.00%
Customer Concentration Risk [Member] | Customer Three [Member] | Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Customer percentage of accounts receivable	19.00%	19.00%
Customer Concentration Risk [Member] | Customer Four [Member] | Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Customer percentage of accounts receivable	18.00%	15.00%

Product_Revenue_Net_Summary_of

Product Revenue, Net - Summary of Provisions and Credit Payments (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Activity of Sales Related Deductions [Roll Forward]
Beginning Balance	$26,735	$1,206
Provision related to current period product revenue	28,779	8,639
Credits/payments	-20,972	-2,095
Ending Balance	$34,542	$7,750

Product_Revenue_Net_Product_Re

Product Revenue, Net - Product Revenue by Customer (Details) (Sales Revenue, Product Line [Member], Customer Concentration Risk [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Customer A [Member]
Concentration Risk [Line Items]
Customer percentage of product revenue	29.00%	29.00%
Customer B [Member]
Concentration Risk [Line Items]
Customer percentage of product revenue	21.00%	19.00%
Customer C [Member]
Concentration Risk [Line Items]
Customer percentage of product revenue	16.00%	12.00%
Customer D [Member]
Concentration Risk [Line Items]
Customer percentage of product revenue	13.00%	8.00%
Customer E [Member]
Concentration Risk [Line Items]
Customer percentage of product revenue	10.00%	13.00%

Collaboration_and_Other_Agreem2

Collaboration and Other Agreements - Background Narrative (Details) (USD $)	1 Months Ended	3 Months Ended
	Dec. 31, 2011	Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum total excess amounts plus interest	$225,000,000
Incremental interest rate for excess amount	2.00%
Maximum Percentage Of Interest On Outstanding Excess Amount (In Percent)	5.00%
Maximum interest on excess amount	25,000,000
Estimated weighted average cost of capital (in percent)	12.00%
Minimum license royalty rates (in percent)	30.00%
Maximum license royalty rates (in percent)	40.00%
Janssen [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sharing percentage pre-tax profit	50.00%
Total excess amounts funded by Janssen		139,200,000
Total Excess Amounts Funded by Janssen		134,300,000
Interest on Outstanding Excess Amount		4,900,000
Pharmacyclics, Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sharing percentage pre-tax profit	50.00%
Licenses [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-Refundable Upfront Payment Upon Execution	70,600,000
Committee Services [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-Refundable Upfront Payment Upon Execution	15,000,000
Services revenue recognized period	17 years
Development Services [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-Refundable Upfront Payment Upon Execution	64,400,000
Services revenue recognized period	9 years
Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-Refundable Upfront Payment Upon Execution	150,000,000
Maximum milestone payments	825,000,000
Percent of cost sharing arrangement Janssen share	60.00%
Percent of cost sharing arrangement by company	40.00%
Company's annual cap of development costs	50,000,000	50,000,000
Collaboration Agreement, Number of Days to Reimburse Collaborative Partner for Outstanding Excess Amounts After Change of Control	30 days
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Continued Development Progress [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payments	250,000,000
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Achievement of Regulatory Progress [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payments	225,000,000	220,000,000
Cumulative milestone payments triggered under collaboration		605,000,000
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Regulatory Approval [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payments	$350,000,000

Collaboration_and_Other_Agreem3

Collaboration and Other Agreements - Pre-tax Profit (Loss) Under the Agreement (Details) (USD $)	1 Months Ended	3 Months Ended
	Dec. 31, 2011	Mar. 31, 2015	Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
50% of Pharmacyclics' U.S. product revenue, net		$189,158,000	$56,179,000
Less: 50% of Pharmacyclics' U.S. cost of goods sold		-16,702,000	-6,110,000
Less: Pharmacyclics' share of research and development costs under the Agreement, net of Excess Amounts		-49,377,000	-35,292,000
Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Less: Pharmacyclics' share of research and development costs under the Agreement, net of Excess Amounts		-27,332,000	-24,402,000
Maximum Cost Sharing Amount Incurred	50,000,000	50,000,000
Pharmacyclic [Member] | IMBRUVICA [Member] | Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
50% of Pharmacyclics' U.S. product revenue, net		94,579,000	28,090,000
Less: 50% of Pharmacyclics' U.S. cost of goods sold		-8,351,000	-3,055,000
Pharmacyclics' 50% share of U.S. net product revenue less cost of goods sold		86,228,000	25,035,000
Less: Pharmacyclics' share of U.S. commercial expenses under the Agreement		-15,083,000	-14,593,000
Pharmacyclics' share of U.S. pre-tax profits from the commercialization of IMBRUVICA under the Agreement		71,145,000	10,442,000
Add: Pharmacyclics' share of ex-U.S. pre-tax commercial profit (loss) under the Agreement (1)		12,525,000	-3,572,000
Pharmacyclics' share of worldwide pre-tax profits from the commercialization of IMBRUVICA under the Agreement		83,670,000	6,870,000
Less: Pharmacyclics' share of research and development costs under the Agreement, net of Excess Amounts		-27,332,000	-24,402,000
Total pre-tax profit (loss) under the Agreement		$56,338,000	($17,532,000)

Collaboration_and_Other_Agreem4

Collaboration and Other Agreements - Collaboration Services and Milestone Revenue (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration services and other revenue	$4,089,000	$3,198,000
License and milestone revenue	0	60,000,000
Total revenue	205,772,000	119,377,000
Deferred revenue, noncurrent	32,757,000		34,885,000
Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
milestone revenue recognized		60,000,000
Deferred revenue	43,900,000
Deferred revenue, noncurrent	32,800,000
Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration services and other revenue	4,089,000	3,135,000
License and milestone revenue	0	60,000,000
Total revenue	$4,089,000	$63,135,000

Collaboration_and_Other_Agreem5

Collaboration and Other Agreements - Janssen Collaboration Cost Sharing (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense	$49,377,000	$35,292,000
Selling, general and administrative	49,505,000	34,715,000
Receivable from collaboration partners	24,025,000		26,970,000
Payable to collaboration partner	77,460,000		79,799,000
Janssen [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payable to collaboration partner	77,500,000		79,800,000
Accrual for Taxes Other than Income Taxes			300,000
Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense	27,332,000	24,402,000
Selling, general and administrative	15,083,000	18,165,000
Receivable from collaboration partners	24,000,000		27,000,000
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Receivable and Product Sales, Milestone Payment One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable from collaboration partners			20,000,000
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Receivable and Product Sales, Milestone Payment Two [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable from collaboration partners			3,900,000
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Value Added Tax [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable from collaboration partners			1,700,000
Counterparty's Share of Pre-tax Commercial Profits [Member] | Janssen [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payable to collaboration partner			76,700,000
Cost-sharing Under the Agreement [Member] | Janssen [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payable to collaboration partner			2,800,000
Collaboration Expense, Unadjusted [Member] | Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense	37,590,000	32,365,000
Selling, general and administrative	20,730,000	18,220,000
Increase (Decrease) for Cost Sharing [Member] | Collaboration and License Agreement with Janssen Biotech Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense	-10,258,000	-7,963,000
Selling, general and administrative	($5,647,000)	($55,000)

Collaboration_and_Other_Agreem6

Collaboration and Other Agreements - Collaboration and License Agreement with Servier (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenue	$205,772	$119,377
Collaboration and License Agreement with Les Laboratories Servier [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenue		$100

Collaboration_and_Other_Agreem7

Collaboration and Other Agreements - License agreement with Novo Nordisk A/S, Narrative (Details) (Collaboration and License Agreement with Novo Nordisk [Member], USD $)	1 Months Ended
	Oct. 31, 2012
Collaboration and License Agreement with Novo Nordisk [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-Refundable Upfront Payment Upon Execution	$5,000,000
Maximum milestone payments	$55,000,000

Collaboration_and_Other_Agreem8

Collaboration and Other Agreements - Celera Corporation, Narrative (Details) (USD $)	1 Months Ended	3 Months Ended
	Apr. 30, 2006	Mar. 31, 2015	Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment for HDAC Inhibitor	two-thirds
Milestone Payment For HDAC Inhibitor Percentage	66.66%
Milestone Payment For Factor VIIa	one-third
Milestone Payment For Factor VIIa Percentage	33.33%
Celera Corporation Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payments	97,000,000
Potential future milestone payments to be paid to Celera after regulatory approval	90.00%
Collaborative agreement, termination terms, days written notice to terminate agreement	60 days
Collaborative agreement, termination terms, days of written notice that breaching party has to cure a breach in contract before termination	90 days
Celera Corporation Agreement [Member] | IMBRUVICA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty Expense		$11,800,000	$3,900,000

Inventory_Narrative_Details

Inventory - Narrative (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$15,415	$0
Work-in-process	26,730	27,591
Finished goods	6,880	6,855
Inventory	$49,025	$34,446

Fair_Value_Measurements_and_Ma2

Fair Value Measurements and Marketable Securities - Available-For-Sale Securities Reconciliation (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities
Amortized Cost	$11,960	$11,960
Unrealized Gain	0	0
Unrealized Loss	-2	-8
Estimated Fair Value	11,958	11,952
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities
Amortized Cost	11,960	11,960
Unrealized Gain	0	0
Unrealized Loss	-2	-8
Estimated Fair Value	$11,958	$11,952

Fair_Value_Measurements_and_Ma3

Fair Value Measurements and Marketable Securities - Contractual Maturities of Marketable Securities (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Assets, Fair Value Disclosure [Abstract]
Less than one year - Amortized Cost	$11,960
Less than one year - Fair Value	$11,958

Fair_Value_Measurements_and_Ma4

Fair Value Measurements and Marketable Securities - Fair Value Measurements for Available-for-sale Securities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities
Marketable Securities, Fair Value	$11,958	$11,952
Level 1 [Member]
Schedule of Available-for-sale Securities
Assets, Fair Value	376,585	373,119
Level 2 [Member]
Schedule of Available-for-sale Securities
Assets, Fair Value	11,958	11,952
Level 3 [Member]
Schedule of Available-for-sale Securities
Assets, Fair Value	0	0
Money market funds [Member] | Level 1 [Member]
Schedule of Available-for-sale Securities
Cash and Cash Equivalents, Fair Value	376,585	373,119
Money market funds [Member] | Level 2 [Member]
Schedule of Available-for-sale Securities
Cash and Cash Equivalents, Fair Value	0	0
Money market funds [Member] | Level 3 [Member]
Schedule of Available-for-sale Securities
Cash and Cash Equivalents, Fair Value	0	0
Certificates of Deposit [Member] | Level 1 [Member]
Schedule of Available-for-sale Securities
Marketable Securities, Fair Value	0	0
Certificates of Deposit [Member] | Level 2 [Member]
Schedule of Available-for-sale Securities
Marketable Securities, Fair Value	11,958	11,952
Certificates of Deposit [Member] | Level 3 [Member]
Schedule of Available-for-sale Securities
Marketable Securities, Fair Value	0	0
Estimated Fair Value [Member]
Schedule of Available-for-sale Securities
Assets, Fair Value	388,543	385,071
Estimated Fair Value [Member] | Money market funds [Member]
Schedule of Available-for-sale Securities
Cash and Cash Equivalents, Fair Value	376,585	373,119
Estimated Fair Value [Member] | Certificates of Deposit [Member]
Schedule of Available-for-sale Securities
Marketable Securities, Fair Value	$11,958	$11,952

Balance_Sheet_Components_Prope

Balance Sheet Components - Property, Plant, and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment
Property, plant and equipment, gross	$44,721	$44,053
Less: Accumulated depreciation and amortization	-12,580	-11,577
Property and equipment, net	32,141	32,476
Equipment [Member]
Property, Plant and Equipment
Property, plant and equipment, gross	20,075	13,363
Leasehold improvements [Member]
Property, Plant and Equipment
Property, plant and equipment, gross	21,677	9,951
Furniture and fixtures [Member]
Property, Plant and Equipment
Property, plant and equipment, gross	1,278	1,278
Construction in Progress [Member]
Property, Plant and Equipment
Property, plant and equipment, gross	$1,691	$19,461

Balance_Sheet_Components_Accru

Balance Sheet Components - Accrued Liabilities and Payables (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]
Accrued discounts and rebates	$25,463	$18,125
Accrued payroll and employee related expenses	19,941	19,645
Accrued clinical related	17,461	14,806
Accrued royalty to Celera	14,924	10,646
Accrued outside services	7,254	5,114
Accrued value added taxes	1,357	7,395
Accrued contract manufacturing	1,355	2,380
Accrued other	7,684	10,168
Total accrued liabilities	$95,439	$88,279

Balance_Sheet_Components_Defer

Balance Sheet Components - Deferred Revenue (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]
Deferred revenue - current portion	$18,797	$18,773
Deferred revenue related to the Agreement (see Note 3)	32,757	34,885
Janssen [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue - current portion	11,172	11,656
Deferred revenue related to the Agreement (see Note 3)	32,757	34,885
Collaboration and License Agreement with Janssen Biotech Inc [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue - current portion	$7,625	$7,117

Intangible_Assets_Details

Intangible Assets - (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Apr. 15, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$179,000	$0
Accumulated amortization	700,000
Future Amortization of Intangible Assets
2015 (remaining 9 months)	548,000
2016	728,000
2017	728,000
2018	728,000
2019	728,000
2020	728,000
Thereafter	4,362,000
Total	8,550,000
Technology-Based Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible acquired technology			9,300,000
Finite-Lived Intangible Asset, Useful Life			13 years
Intellectual Property [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$200,000

Income_Taxes_Narrative_Details

Income Taxes - Narrative (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Income tax provision (benefit) (less than)	$86	($12)
Federal statutory income tax rate	35.00%

Commitments_and_Contingencies_1

Commitments and Contingencies - Narrative (Details) (USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	Jan. 31, 2015	Feb. 28, 2015	Dec. 31, 2014
	sqft	sqft	sqft
Commitments and Contingencies [Line Items]
Noncancelable purchase obligation	76,800,000			$85,900,000
Operating Lease Commitments
2015 (remaining 9 months)	2,376,000
2016	2,752,000
2017	2,143,000
2018	857,000
2019	882,000
2020	909,000
Thereafter	1,981,000
Total	11,900,000
Janssen [Member]
Commitments and Contingencies [Line Items]
Total excess amounts funded by Janssen	139,200,000
Total Excess Amounts Funded by Janssen	134,300,000
Interest on Outstanding Excess Amount	4,900,000
Corporate Headquarters [Member]
Commitments and Contingencies [Line Items]
Facility Total Leased Space in Square Feet, Current	168,189
Facility Total Leased Space in Square Feet	79,776
Period for which option to extend lease term is available	5 years
California [Member]
Commitments and Contingencies [Line Items]
Facility Total Leased Space in Square Feet	52,400
California [Member] | Corporate Headquarters [Member]
Commitments and Contingencies [Line Items]
Facility Total Leased Space in Square Feet		36,000
Operating Leases, Rent Expense		500,000
California [Member] | Building [Member]
Commitments and Contingencies [Line Items]
Facility Total Leased Space in Square Feet			10,000
Operating Leases, Rent Expense			$400,000
Switzerland [Member]
Commitments and Contingencies [Line Items]
Facility Total Leased Space in Square Feet, Current	8,000
South San Francisco, California [Member]
Commitments and Contingencies [Line Items]
Facility Agreement, Additional Leased Space, Square Feet	7,000

Basic_and_Diluted_Net_Income_P2

Basic and Diluted Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net income	$4,147	$18,275
Denominator:
Weighted average common shares - basic (in shares)	76,205	74,754
Weighted average common shares - diluted (in shares)	79,231	78,064
Net income per share:
Basic (in dollars per share)	$0.05	$0.24
Diluted (in dollars per share)	$0.05	$0.23
Potentially dilutive securities excluded from net income per share - diluted because their effect is anti-dilutive (in shares)	43	658
Employee Stock Option [Member]
Denominator:
Effect of Dilutive Securities (in shares)	2,806	3,306
Employee Stock [Member]
Denominator:
Effect of Dilutive Securities (in shares)	95	4
Restricted Stock Units (RSUs) [Member]
Denominator:
Effect of Dilutive Securities (in shares)	125	0

StockBased_Compensation_and_St2

Stock-Based Compensation and Stockholders' Equity - Share-based Compensation Recognized in Statements of Operations (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$23,496	$12,986
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	425	417
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	10,432	5,535
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$12,639	$7,034

StockBased_Compensation_and_St3

Stock-Based Compensation and Stockholders' Equity - Stock Option Activity (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock Options, Outstanding, Number of Shares Beginning	4,200
Stock Options, Exercised, Number of Shares	-855
Stock Options, Granted, Number of Shares	400
Stock Options, Forfeited, Number of Shares	-35
Stock Options, Outstanding, Number of Shares Ending	3,710
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Stock Options, Outstanding, Weighted Average Exercise Price Beginning (in dollars per share)	$43.50
Stock Options, Exercised, Weighted Average Exercise Price (in dollars per share)	$21.45
Stock Options, Granted, Weighted Average Exercise Price (in dollars per share)	$80.78
Stock Options, Forfeited, Weighted Average Exercise Price (in dollars per share)	$92.03
Stock Options, Outstanding, Weighted Average Exercise Price Ending (in dollars per share)	$52.13

StockBased_Compensation_and_St4

Stock-Based Compensation and Stockholders' Equity - Restricted Stock Units Activity (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Number of Shares Underlying Restricted Stock Units (RSUs)
Beginning Balance, Shares	188
Granted, Shares	174
Released, Shares	-6
Forfeited, Shares	-4
Ending Balance, Shares	352
Restricted Stock Units (RSUs)
Beginning Balance, Weighted Average Grant Date Fair Value	$115.32
Granted, Weighted Average Grant Date Fair Value	$159.26
Released, Weighted Average Grant Date Fair Value	$135.51
Forfeited, Weighted Average Grant Date Fair Value	$100.42
Ending Balance, Weighted Average Grant Date Fair Value	$136.82

StockBased_Compensation_and_St5

Stock-Based Compensation and Stockholders' Equity - Narrative (Details) (USD $)	3 Months Ended
Share data in Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of performance options granted with performance goals not set (less than) (in shares)	0.4
Number of performance RSUs granted with performance goals not set (less than) (in shares)	0.1
Adjustments to additional paid in capital, other	$59,300,000
Share-based Compensation	23,600,000
Proceeds from issuance of common stock under employee stock plans	18,226,000	5,180,000
Income tax benefit from stock-based compensation arrangements	18,000,000
Time Based Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	600,000
Equity Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for purchase under the plan (in shares)	1.8
PurchasePlan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for purchase under the plan (in shares)	0.5
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock under employee stock plans	$18,300,000
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Related_Party_Transactions_Det

Related Party Transactions (Details) (Director [Member], USD $)	3 Months Ended		0 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Jan. 22, 2015	Dec. 31, 2014
Legal Counsel [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$0.90	$0.80
Legal Counsel [Member] | Accrued Liabilities [Member]
Related Party Transaction [Line Items]
Due to Related Parties	3.4			1.3
Consulting Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Related Party Transaction [Line Items]
Restricted stock units granted (in shares)			10,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms			4 years
Accounts Payable, Related Parties			1.6
Consulting Agreement Out of Pocket Expenses [Member]
Related Party Transaction [Line Items]
Maximum Payments Provided for in Consulting Agreements			$0.10

Pending_Agreement_and_Plan_of_1

Pending Agreement and Plan of Reorganization with AbbVie Inc. - Narrative (Details) (AbbVie Inc. [Member], Pharmacyclics, Inc. [Member], Scenario, Plan [Member], USD $)	0 Months Ended
	Mar. 23, 2015
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$21,000,000,000
Loss on Contract Termination	$680,000,000
Cash [Member]
Business Acquisition [Line Items]
Business Acquisition, Share Price	$261.25
Stock Distribution [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Fair Market Value Per Share	$261.25
Cash and Stock Distribution [Member]
Business Acquisition [Line Items]
Business Acquisition, Share Price	$152.25
Business Acquisition, Equity Interest Issued or Issuable, Fair Market Value Per Share	$109